A small biotech company tries to move to the next level: jump through the final hoops with the FDA and bring its product to market. This is its story. It’s a sponsored post, part of our series where we highlight small companies on the move [Wolf].
A little-known biotech company is poised to potentially produce millions in revenue with the planned release of a breakthrough technology that could prevent strokes with a test that is affordable and accessible.
A Multi-Billion-Dollar Problem with a $49,000 Answer
Stroke statistics are shocking: Globally, every year 15 million people suffer a stroke. Of these, some 6 million die from it, while 5 million are rendered permanently disabled. In the U. S. alone, nearly 800,000 people suffer from strokes annually – and someone dies of a stroke every 4 minutes.
Until now, there has been no cost-effective way to screen for Ischemia, the leading indicator of a stroke, which cost the U. S. government alone tens of billions of dollars a year. That could be about to change, thanks to a breakthrough technology from CVR Medical (TSX:CVM. V ; OTC:CRRVF. The company’s debut, game-changing medical device has been quietly in development for 10 years, and now it’s about to charge out of the gate, hoping to take the market by storm upon FDA market clearance.
What 3D seismic imagery did for super quick discoveries in the oil and gas industry, CVR’s sensory system could do for the medical industry.
This post was published at Wolf Street By James Burgess, Sponsored Post ‘ Jan 17, 2017.
Follow on Twitter
Recent Comments